Go to Cognosci home page
Company spacer Technology spacer Pipeline spacer Partnering spacer News


neurons




Company
 
   bullet  About Us

   bullet  Management

   bullet  Advisors

   bullet  Contact Us



Technology

   bullet  APOE and Human
   bullet  Disease

   bullet  APOE and
   bullet  Inflammation

   bullet  Cognosci APOE
   bullet  Compounds

   bullet  Publications



Pipeline

   bullet  Multiple Sclerosis

   bullet  Traumatic Brain
   bullet  Injury

   bullet  Subarachnoid
   bullet  Hemorrhage

   bullet  Rheumatoid Arthritis

   bullet  Ischemic Stroke

   bullet  Sepsis

   bullet  Alzheimer’s Disease

   bullet  Parkinson’s Disease



Partnering

   bullet  Multiple Sclerosis

   bullet  Alzheimer’s Disease

   bullet  Subarachnoid
   bullet  Hemorrhage



News

   bullet  Latest News

 spacer

Partnering


While Cognosci plans to initiate human clinical trials of compounds to treat Multiple Sclerosis and Subarachnoid Hemorrhage by the end of 2008, the Company intends to maintain focus on using our established expertise in discovery and development of novel therapeutics for diseases that cause severe disability or that are life threatening rather than shifting to a marketing and sales based company. Therefore, we seek pharmaceutical partners for advanced development and commercialization of our programs in preclinical and clinical development. The current opportunities available for licensing are described in the following white papers:



For more information contact:

Michael P. Vitek, Ph.D.
CEO
E-mail:
Phone: (1) 919-765-0028, extension 1



spacer Latest News

Cognosci Receives Funding for Advanced Testing of Lead Drug Candidate for the Treatment of Multiple Sclerosis
more...





For more information, contact:

Cognosci Inc.
79 T. W. Alexander Drive
4401 Research Commons
Research Triangle Park
NC 27709
(919) 765-0028